Frédéric Sedel

Dr. Frédéric Sedel is a French neurologist and the current Chief Medical Officer at OTR3. Frédéric was previously the Chief Scientific Officer at Medday-Pharmaceuticals from September 2018 to July 2020, and a Founding Board Member and Co-founder/CEO at MedDay Pharmaceuticals from November 2013 to January 2021. Prior to that, they were a Senior Staff Neurologist at the Department of Neurology at Assistance publique- hopitaux de paris from October 2006 to October 2013. There, they also served as the coordinator of a Neuro-Metabolic unit and a Clinical Neurometabolic Research Group (Pierre&Marie Curie University, Paris, France) from 2011 to 2013.

Frédéric Sedel has a Habilitation à diriger les recherches from the University Pierre et Marie Curie (Paris VI) in the field of medicine. Frédéric also has a PhD from the Ecole Normale Supérieure in the field of neurosciences. Frédéric completed their medical studies and residency in neurology at the Pitié-Salpêtrière Faculty of Medicine. Frédéric also has a master's degree from the University Paris XII in the field of immunology and molecular biology.

Their manager is Denis Barritault, President. Some of their coworkers include Laurent Pinchard - COO, Agnès Choppin - Chief Scientific Officer, and Aly Karamoko - CFO.